Evidence map›Paper›PMID 36012349›Full record

ReviewInternational journal of molecular sciences2022

Cellular Mechanisms Underlying the Cardioprotective Role of Allicin on Cardiovascular Diseases.

José L Sánchez-Gloria, Abraham S Arellano-Buendía, Juan G Juárez-Rojas, Fernando E García-Arroyo, Raúl Argüello-García, Fausto Sánchez-Muñoz, Laura G Sánchez-Lozada, Horacio Osorio-Alonso

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Chemical Complexity of Food and Implications for Therapeutics.The New England journal of medicine · 2025
    Review
  10. Antibacterial Activity ofJournal of microbiology and biotechnology · 2025
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Leveraging Therapeutic Proteins and Peptides fromInternational journal of molecular sciences · 2024
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

José L Sánchez-GloriaSección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.
Abraham S Arellano-BuendíaDepartment of Cardio-Renal Physiopathology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.
Juan G Juárez-RojasDepartment of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0001-8864-2304
Fernando E García-ArroyoDepartment of Cardio-Renal Physiopathology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0003-1545-9765
Raúl Argüello-GarcíaDepartamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del IPN, Mexico City 07360, Mexico.
Fausto Sánchez-MuñozDepartment of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0001-6556-1632
Laura G Sánchez-LozadaDepartment of Cardio-Renal Physiopathology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0003-0348-9617
Horacio Osorio-AlonsoDepartment of Cardio-Renal Physiopathology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0002-9238-4202
Instituto Nacional de Cardiología · MXInstituto Politécnico Nacional · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) are a group of diseases in which the common denominator is the affection of blood vessels, heart tissue, and heart rhythm. The genesis of CVD is complex and multifactorial; therefore, approaches are often based on multidisciplinary management and more than one drug is used to achieve the optimal control of risk factors (dyslipidemia, hypertension, hypertrophy, oxidative stress, endothelial dysfunction, inflammation). In this context, allicin, a sulfur compound naturally derived from garlic, has shown beneficial effects on several cardiovascular risk factors through the modulation of cellular mechanisms and signaling pathways. Effective pharmacological treatments for CVD or its risk factors have not been developed or are unknown in clinical practice. Thus, this work aimed to review the cellular mechanisms through which allicin exerts its therapeutic effects and to show why it could be a therapeutic option for the prevention or treatment of CVD and its risk factors.

Indexed as

Cardiovascular DiseasesGarlicDisulfidesHumansSulfinic AcidsallicinDisulfidesSulfinic Acidsallicincardiovascular diseasedyslipidemiaendothelial dysfunctionhypertensionhypertrophyinflammationoxidative stressrisk factors

Identifiers

PMID36012349
PMCPMC9409331
OpenAlexW4291465456

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.